If patent protection has been carefully arranged for, other makers will not be able to mimic the drug and grab a share of the market. To be sure, this big-money, high-risk, winner-take-all approach is totally different from the way the business has been practiced for the past several decades in Taiwan, where makers have traditionally stuck to the generic drug market, which offers thinner but more dependable profits.
不可否認，這種超高投資、超高風險而「贏家通吃」的產業運轉模式，迥異於國內製藥業數十年來主攻「學名藥」市場的商業模式。所謂學名藥，是指國際大廠藥物專利過期後，其他藥廠可依據其公開資訊「仿製」該種藥品，以求取微薄但穩健的獲利。